Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) SVP Arjun Agarwal sold 533 shares of the business’s stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $95.75, for a total transaction of $51,034.75. Following the transaction, the senior vice president owned 14,219 shares of the company’s stock, valued at approximately $1,361,469.25. This trade represents a 3.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Arjun Agarwal also recently made the following trade(s):
- On Tuesday, September 15th, Arjun Agarwal sold 560 shares of Oruka Therapeutics stock. The shares were sold at an average price of $95.71, for a total transaction of $53,597.60.
- On Friday, September 11th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The stock was sold at an average price of $92.23, for a total transaction of $872,403.57.
- On Thursday, August 13th, Arjun Agarwal sold 10,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $106.66, for a total transaction of $1,066,600.00.
- On Monday, July 13th, Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock. The stock was sold at an average price of $84.63, for a total value of $846,215.37.
Oruka Therapeutics Trading Down 1.7%
Shares of ORKA traded down $1.58 during midday trading on Monday, hitting $93.38. 1,185,411 shares of the company’s stock traded hands, compared to its average volume of 1,098,345. Oruka Therapeutics, Inc. has a 1 year low of $14.89 and a 1 year high of $115.51. The firm’s fifty day moving average is $96.40 and its 200-day moving average is $74.07. The stock has a market capitalization of $6.18 billion, a price-to-earnings ratio of -46.00 and a beta of -0.34.
Institutional Trading of Oruka Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ORKA. BlackRock Inc. acquired a new position in shares of Oruka Therapeutics in the second quarter valued at about $474,916,000. Jupiter Topco LLC acquired a new stake in shares of Oruka Therapeutics during the second quarter worth about $130,968,000. Bank of America Corp DE purchased a new stake in Oruka Therapeutics in the second quarter valued at approximately $33,578,000. Braidwell LP purchased a new stake in Oruka Therapeutics in the second quarter valued at approximately $26,473,000. Finally, Atika Capital Management LLC acquired a new position in Oruka Therapeutics in the 1st quarter worth approximately $11,277,000. Institutional investors and hedge funds own 56.44% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on ORKA shares. Mizuho set a $120.00 price target on Oruka Therapeutics in a research note on Thursday, September 3rd. BTIG Research reaffirmed a “buy” rating and issued a $151.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. UBS Group lifted their target price on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Piper Sandler reissued an “overweight” rating and set a $180.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Finally, Guggenheim restated a “buy” rating and set a $200.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $133.00.
Read Our Latest Report on Oruka Therapeutics
About Oruka Therapeutics
Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.
Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.
Read More
- Five stocks we like better than Oruka Therapeutics
- Can Bloom Energy Pop the Top Off AI’s Massive Energy Bottleneck?
- Coach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback
- AI Is Reshaping SaaS—These 2 Software ETFs Offer Different Ways to Play It
- Insiders Signal Deep Value In DICK’s Sporting Goods
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
